Citius Pharmaceuticals, Inc. — Director's Dealing 2018

Aug 15, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2018-08-13

Reporting Person: HOLUBIAK MYRON Z (Director, President and CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-13	Common Stock	P	784314	$1.275	Acquired	1304196	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-13	Warrant to Purchase Common Stock	$1.15	A	784314	Acquired	2023-08-14	Common Stock (784314)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Purchase Common Stock	$8.10	2025-10-01	Common Stock (26667)	26667	Direct
Options to Purchase Common Stock	$3.45	2027-09-13	Common Stock (40000)	40000	Direct
Warrant to Purchase Common Stock	$6.21	2019-06-12	Common Stock (19615)	19615	Direct

Footnotes

F1: The warrant is fully vested and exercisable immediately.

F2: The purchase price of the warrants was included in the purchase price of the common stock reported in Table I.

F3: The option granted vested and became exercisable as follows: the option to purchase 2,667 shares of common stock of the Company (the "Common Stock") vested on October 1, 2015, and the balance of the option to purchase shares of Common Stock vested in twelve (12) equal installments commencing on December 31, 2015.

F4: One-third of the shares of the Company's common stock underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of the Company's common stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest.